President Donald Trump has broadened the reach of his most-favored-nation drug pricing deals to cover Medicaid programs across the entire country, including Puerto Rico and D.C.. This Friday announcement aims to ensure that low-income,senior, and disabled populations receive the lowest negotiated rates for medications.
The 26 pharmaceutical companies involved in the MFN deals
Since late September 2025, the Trump administratioon has been negotiating with a massive group of drug manufacturers to lower costs. According to the report, the administration has already reached agreements with 26 different pharmaceutical companies. this group includes major global players such as Eli Lilly, AstraZeneca, Merck, Novartis, and Johnson & Johnson, as well as companies like Amgen, GSK, and Sanofi.
The scope of these deals covers a wide variety of manufacturers, ranging from Teva Pharmaceuticals and Sun Pharma to Novo Nordisk and Bristol Myers Squibb. By bringing these 26 entities into the most-favored-nation framework, the administration intends to standardize lower pricing across the entire Medicaid landscape, rather than leaving it to individual state negotiations.
Using the GENEROUS Medicaid Payment Model to bridge price gaps
The expansion relies on a specific mechanism to ensure that Medicaid programs actually realize these lower prices. While Medicaid currently negotiates with manufacturers, federal law prevents the program from paying more than the "average manufacturer price." As reported by the source, this average price is frequently higher than the MFN rates established by the Trump administration.
To solve this discrepancy, the Treasury Department is requiring pharmaceutical companies to provide rebates through the GENEROUS Medicaid Payment Model. This model is designed to close the financial gap, ensuring that the final price paid by Medicaid for expensive brand-name drugs does not exceed the negotiated MFN rate. This administrative workaround is the linchpin that allows the MFN benefits to reach state-run programs.
The $4 billion taxpayer savings projected for 2025
The financial implications of this policy are substantial,according to White House estimates. The administration expects that extending these agreements to all state Medicaid programs will save taxpayers nearly $4 billion in 2025 alone. This represents a significant shift in how federal and state funds are allocated for prescription drug coverage.
President Trump noted during his Friday announcement that these savings could provide a massive boost to state budgets. He suggested that "every state will now have the ability to use those extra billions of dollars to invest in other healthcare improvements or something else," effectively turning drug price negotiations into a broader tool for state-level healthcare funding.
Potential legal hurdles for the Treasury's rebate mandate
Despite the administration's optimism, several critical questions remain regarding the implementation of this policy. The source does not clarify whether any of the 26 pharmaceutical companies have signaled an intent to challenge the Treasury Department's rebate requirements in court. Given the scale of the savings, a legal battle over the GENEROUS Medicaid Payment Model is a distinct possibility.
Furthermore, it is currently unknown how individual states will manage the logistics of receiving these rebates or how quickly the savings will manifest for beneficiaries.. While the administration has set a clear target for 2025, the actual speed of implementation and the level of cooperation from state-run Medicaid offices remain unverified.
Comments 0